The increase in cardiac output and the increase in resting heart rate during Supraventricular tachycardia (SVT) can be defined as an abnormally rapid heart rhythm originating above the ventricles, often (but not always) with a narrow QRS complex; it conventionally excludes atrial flutter and atrial fibrillation [ 1 ]
There are almost no controlled trials, and medication choices are not
Although meta-analysis did not indicate a significant effect of beta-blockers on arterial hypotension or bradycardia, propranolol dosage in one study was reduced by 50% in
study of a comparison of digoxin and propranolol for chronic therapy of supraventricular tachycardia (SVT) in infants <4 months of age
The Study of Antiarrhythmic Medications in Infancy (SAMIS) [33], a randomized, double-blind, multicenter study of infants with SVT, excluding Wolff
1 Altmetric Explore all metrics Abstract Supraventricular tachycardia (SVT) is a common infant arrhythmia, for which beta-blockers are frequently chosen as
We excluded infants discharged prior to completing 2 days of therapy, those with Wolff
It appears that propranolol can play an important role in treatment of supraventricular arrhythmias of childhood unresponsive to conventional therapy
Some of the medical interventions beneficial in the first and second trimester result in In some patients with AFL, antiarrhythmic therapy such as digoxin and propranolol can be used as maintenance therapy
Propranolol improved the dysrhythmia in 31 of 41 patients, being notably effective in supraventricular tachycardia and ventricular tachycardia associated with a prolonged QT interval
Initially 20–50 micrograms/kg every 6–8 hours, adjusted according to response, to be given over 10 minutes
For oral dosage form (tablets): Adults—80 to 320 milligrams (mg) per day, given in divided doses
In most instances, life-threatening tachycardia can Objectives: Supraventricular tachycardia is the most common arrhythmia in infants, and antiarrhythmic medications are frequently used for prophylaxis
The first episode of an SVT occurs during the first year of life in 50–60%, predominantly in the first 3–4 months [4–7]
These blood vessels form benign (non-cancerous) growths that can develop into ulcers or red marks on the skin
Supraventricular tachycardia in children: clinical features, response to treatment, and long-term follow
The fussiness seen in our first patient may have reflected Less serious side effects include: nausea (feeling sick), vomiting cold hands or feet
short-term memory loss
Characterization of supraventricular tachycardia in infants: clinical and instrumental diagnosis
Greater than a third of new onset SVT occurs in the first few weeks of life, commonly presenting after many hours with signs of heart failure
The indications for treatment are limitation or interference with
Long-term efficacy and safety of atenolol for supraventricular tachycardia in children Pediatr Cardiol
Some newborns can be quite unwell if they have had SVT in the womb for a long time
Goal dosing is 2–4 mg/kg/day, although, rarely, patients can require up to the maximum dose of 16 or 60 mg/day to achieve arrhythmia control